Hypofractionated radiation therapy can halve treatment time for poor performance status lung cancer patients : medicalxpress

As it stated in medicalxpress

Hypofractionated radiation therapy can halve treatment time for poor performance status lung cancer patients

Hypofractionated radiation therapy can halve treatment time for poor performance status lung cancer patients

For patients with stage II and III non-small cell lung cancer (NSCLC) unable to receive standard treatments of surgery or chemoradiation (CRT), hypofractionated radiation therapy (RT) results in similar overall survival (OS) and progression-free survival (PFS) rates, limited severe side effects and shorter treatment times when compared to conventional RT, according to research presented today at the 58th Annual Meeting of the American Society for Radiation Oncology (ASTRO).NSCLC is responsible for the most cancer-specific deaths globally, and many of these deaths are associated with the high percentage of patients who present with stage III cancer upon diagnosis.Additionally, due to other medical issues or poor performance status (a measure that considers a patient's quality of life and ability to function during treatment), some stage III NSCLC patients are unable to receive the standard treatment of concurrent chemotherapy and RT.


in the same way medicalxpress

Extremely hypofractionated radiation therapy shows promising results for intermediate risk prostate cancer patients

Extremely hypofractionated radiation therapy shows promising results for intermediate risk prostate cancer patients

For men with intermediate risk prostate cancer, side effects at two years following radiation therapy (RT) were comparable for extremely-hypofractionated treatment, which was delivered in seven fractions across two and a half weeks, and conventional treatment of 39 fractions across eight weeks, according to research presented today at the 58th Annual Meeting of the American Society for Radiation Oncology (ASTRO).The HYPO-RT-PC trial, a randomized multi-institutional phase III trial in Scandinavia, was designed to assess outcomes from highly accelerated extreme hypofractionation, which is delivered in smaller number of high doses—seven fractions of 6.1 Gy each in this study."Randomized trials have confirmed the value of radiation dose escalation for prostate tumors, and the potential benefits of larger radiation doses in fewer fractions, are expected to increase the therapeutic efficacy for men with prostate cancer," said Anders Widmark, MD, a professor of radiation sciences at Umeå University in Umeå, Sweden and lead author of the study.


moreover from scnow

Prostate cancer options vary from 'watchful waiting' to radiation therapy

Prostate cancer options vary from 'watchful waiting' to radiation therapy

Florence, SC (29506)TodayConsiderable clouds this morning.Some decrease in clouds later in the day.A stray shower or thunderstorm is possible.